Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-09-23
Original SEC Filing: Click here

---

Webplus: SVA/20200923/6-K/2_EX-99.1/000.htm SEC Original: tm2031596d2_ex99-1.htm
Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ — Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today th This randomized, double-blinded, and placebo-controlled phase I/II clinical trial among adolescents and children between

---

---

Webplus: SVA/20200923/6-K/1/000.htm SEC Original: tm2031596d2_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-09-23CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200